Premium
Results of Transurethral Resection Plus Adjuvant Intravesical Chemotherapy for Superficial Bladder Cancer
Author(s) -
Nomi Masashi,
Gohji Kazuo,
Okamoto Masayuki,
Takenaka Atsushi,
Ono Yoshiharu,
Fujii Akio
Publication year - 1998
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1998.tb00407.x
Subject(s) - medicine , concomitant , bladder cancer , cystectomy , urology , carcinoma in situ , stage (stratigraphy) , chemotherapy , surgery , cancer , paleontology , biology
Background : We analyzed the results of conservative therapy for superficial bladder cancer to determine the risk factors for recurrence and progression. Methods : Between May 1984 and February 1997, 111 patients with primary superficial bladder cancer were treated by a transurethral resection with or without intravesical instillation of chemotherapy, or for patients with concomitant carcinoma in situ (CIS), bacillus Calmette‐Guerin. We examined the relationship between tumor stage, grade, incidence of concomitant CIS and recurrence‐free survival according to pathologic findings and the drugs instilled. Results : The incidence of concomitant CIS in pTI, grade 3 tumors was significantly higher than that in pTa, grade 1 tumors (42% vs. 3%, P= 0.006). The 5‐year recurrence‐free survival rate of all patients was 73%. There was no significant difference in recurrence‐free survival and pathologic stage, tumor grade, presence of concomitant CIS, or drugs used for instillation. However, the recurrence‐free survival in patients with 5 tumors was significantly lower than in patients with less than 5 tumors. Of the 111 patients, only 3 patients demonstrated disease progression and underwent a radical cystectomy, while 1 patient with a pTI b, grade 3 tumor developed a tumor in the ureter. No patient died of bladder cancer. Conclusion : Our results indicate that the prognosis of superficial bladder cancer patients with a high‐stage, high‐grade (pTI, grade 3) tumor is favorable when treated by a transurethral resection and intravesical instillation. Bacillus Calmette‐Guerin therapy is useful to prevent the recurrence of tumors with concomitant CIS.